{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T02:05:48Z","timestamp":1787191548238,"version":"build-2736575974"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"DOI":"10.2146\/ajhp150749","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T19:56:18Z","timestamp":1463860578000},"page":"797-809","source":"Crossref","is-referenced-by-count":14,"title":["Specialty pharmacy for hematologic malignancies"],"prefix":"10.1093","volume":"73","author":[{"given":"Susan","family":"Fajardo","sequence":"first","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Zook","sequence":"additional","affiliation":[{"name":"Froedtert and the Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Dotson","sequence":"additional","affiliation":[{"name":"James Cancer Hospital, Ohio State Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102522423100_b1-ajhp797","first-page":"231","article-title":"Adherence to targeted oral anticancer medications","volume":"15","author":"Geynismun","year":"2013","journal-title":"Discov Med"},{"issue":"suppl 3","key":"key\n\t\t\t\t2019041102522423100_b2-ajhp797","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"key\n\t\t\t\t2019041102522423100_b3-ajhp797","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphoma, v.2.2015. www.nccn.org (accessed 2015 Aug 15)."},{"key":"key\n\t\t\t\t2019041102522423100_b4-ajhp797","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b5-ajhp797","volume-title":"Imbruvica (ibrutinib) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b6-ajhp797","article-title":"Single agent ibrutinib (pci-32765) is highly effective in chronic lymphocytic leukemia patients with 17p deletion (abstract 008)","author":"Wiestner"},{"key":"key\n\t\t\t\t2019041102522423100_b7-ajhp797","volume-title":"Zydelig (idelalisib) package insert","year":"2014"},{"key":"key\n\t\t\t\t2019041102522423100_b8-ajhp797","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b9-ajhp797","doi-asserted-by":"crossref","first-page":"77S","DOI":"10.1592\/phco.30.pt2.77S","article-title":"Current and future clinical strategies in the management of chronic myeloid leukemia","volume":"30","author":"Rao","year":"2010","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041102522423100_b10-ajhp797","unstructured":"American Cancer Society. Cancer facts and figures 2016. www.cancer.org\/acs\/groups\/content\/@research\/documents\/document\/acspc-047079.pdf (accessed 2016 Jan 13)."},{"key":"key\n\t\t\t\t2019041102522423100_b11-ajhp797","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","article-title":"Current and emerging treatment options in chronic myeloid leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041102522423100_b12-ajhp797","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b13-ajhp797","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b14-ajhp797","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b15-ajhp797","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b16-ajhp797","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b17-ajhp797","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b18-ajhp797","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (abstract 1126)","author":"Deininger"},{"key":"key\n\t\t\t\t2019041102522423100_b19-ajhp797","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b20-ajhp797","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b21-ajhp797","doi-asserted-by":"crossref","unstructured":"Hochhaus A , KimDW, ShahNP. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response (abstract 653). https:\/\/ash.confex.com\/ash\/2013\/webprogram\/Paper63710.html (accessed 2016 Feb 22).","DOI":"10.1182\/blood.V122.21.653.653"},{"key":"key\n\t\t\t\t2019041102522423100_b22-ajhp797","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b23-ajhp797","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b24-ajhp797","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041102522423100_b25-ajhp797","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b26-ajhp797","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: chronic myelogenous leukemia, v.1.2015. www.nccn.org (accessed 2015 Aug 8)."},{"key":"key\n\t\t\t\t2019041102522423100_b27-ajhp797","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b28-ajhp797","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b29-ajhp797","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales (2013). www.fda.gov\/Drugs\/DrugSafety\/ucm373040.htm (accessed 2015 Aug 15)."},{"key":"key\n\t\t\t\t2019041102522423100_b30-ajhp797","doi-asserted-by":"crossref","unstructured":"American Cancer Society. Multiple myeloma. www.cancer.org\/cancer\/multiplemyeloma\/index (accessed 2016 Feb 22).","DOI":"10.1158\/1078-0432.CCR-16-0625"},{"key":"key\n\t\t\t\t2019041102522423100_b31-ajhp797","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: myeloma. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (accessed 2015 Aug 31)."},{"key":"key\n\t\t\t\t2019041102522423100_b32-ajhp797","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b33-ajhp797","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b34-ajhp797","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041102522423100_b35-ajhp797","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: multiple myeloma, v.2.2015. www.nccn.org (accessed 2015 Aug 31)."},{"key":"key\n\t\t\t\t2019041102522423100_b36-ajhp797","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b37-ajhp797","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma","volume":"154","author":"Bird","year":"2011","journal-title":"Br J Heam"},{"key":"key\n\t\t\t\t2019041102522423100_b38-ajhp797","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b39-ajhp797","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2162-3619-1-27","article-title":"Thalidomide and its analogues in the treatment of multiple myeloma","volume":"1","author":"Latif","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b40-ajhp797","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b41-ajhp797","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102522423100_b42-ajhp797","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041102522423100_b43-ajhp797","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0953-6205(08)60041-2","article-title":"Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients >75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01\/01","volume":"19","author":"Hulin","year":"2008","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t2019041102522423100_b44-ajhp797","volume-title":"Thalomid (thalidomide) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b45-ajhp797","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/asheducation-2010.1.423","article-title":"Dealing with neuropathy in plasma-cell dyscrasias","volume":"2010","author":"Sonneveld","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t2019041102522423100_b46-ajhp797","volume-title":"Revlimid (lenalidomide) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b47-ajhp797","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1182\/blood-2010-08-303487","article-title":"Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)","volume":"116","author":"Zonder","year":"2010","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b48-ajhp797","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b49-ajhp797","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b50-ajhp797","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b51-ajhp797","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041102522423100_b52-ajhp797","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","article-title":"Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma","volume":"22","author":"Paripati","year":"2008","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019041102522423100_b53-ajhp797","volume-title":"Pomalyst (pomalidomide) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b54-ajhp797","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b55-ajhp797","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","article-title":"Histone deacetylase (HDAC) inhibitors in recent trials for cancer therapy","volume":"1","author":"Wagner","year":"2010","journal-title":"Clin Epigenetics"},{"key":"key\n\t\t\t\t2019041102522423100_b56-ajhp797","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b57-ajhp797","volume-title":"Farydak (panobinostat) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b58-ajhp797","volume-title":"Ninlaro (ixazomib) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b59-ajhp797","doi-asserted-by":"crossref","unstructured":"Moreau P , MassziT, GrzaskoN. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline\u2013MM1 Study (NCT01564537). https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper79829.html (accessed 2016 Feb 22).","DOI":"10.1182\/blood.V126.23.727.727"},{"key":"key\n\t\t\t\t2019041102522423100_b60-ajhp797","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"Pl3\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Eng J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b61-ajhp797","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102522423100_b62-ajhp797","doi-asserted-by":"crossref","unstructured":"Zinzani PL , VoseJM, CzuczmanMS. Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed\/refractory mantle cell lymphoma: long-term follow-up analysis of the NHL-003 study. https:\/\/ash.confex.com\/ash\/2012\/webprogram\/Paper47949.html (accessed 2016 Feb 22).","DOI":"10.1182\/blood.V120.21.2738.2738"},{"key":"key\n\t\t\t\t2019041102522423100_b63-ajhp797","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"key\n\t\t\t\t2019041102522423100_b64-ajhp797","volume-title":"Targretin (bexarotene) package insert","year":"2013"},{"key":"key\n\t\t\t\t2019041102522423100_b65-ajhp797","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041102522423100_b66-ajhp797","volume-title":"Intron A (interferon alfa-2b) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041102522423100_b67-ajhp797","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041102522423100_b68-ajhp797","article-title":"Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy","author":"Suzuki","journal-title":"J Oncol Pharm Pract"},{"key":"key\n\t\t\t\t2019041102522423100_b69-ajhp797","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11096-014-0029-4","article-title":"Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience","volume":"36","author":"Lopez-Martin","year":"2014","journal-title":"Int J Clin Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/11\/797\/28334433\/ajhp0797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T15:07:05Z","timestamp":1600614425000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/11\/797\/5101536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150749","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,6,1]]}}}